Effectiveness and safety of vedolizumab induction with or without budesonide in patients with moderately to severely active Crohn’s disease in Europe: a retrospective observational study

Abstract Background Vedolizumab (VDZ), a gut-selective anti-lymphocyte trafficking integrin antibody, is effective in treating patients with moderately to severely active Crohn’s disease (CD). In this study, we examined the real-world effectiveness and safety of induction therapy using VDZ alone or...

詳細記述

書誌詳細

主要な著者:	Roni Weisshof, Stephan R. Vavricka, Lieven Pouillon, Fiona Braegger, Montserrat Roset, Nawal Bent-Ennakhil, Marc Ferrante
フォーマット:	Artigo
言語:	Inglês
出版事項:	BMC 2023-11-01
シリーズ:	BMC Gastroenterology
主題:	Budesonide Crohn’s disease Moderately to severely active crohn’s disease Vedolizumab
オンライン･アクセス:	https://doi.org/10.1186/s12876-023-03032-7
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!